Healthy
Conditions
Brief summary
Subjects to compare the single dose bioavailability of Torrent's Esomeprazole Mg DR Capsule 1×40 mg and Nexium 40 mg DR Capsule containing Esomeprazole 40 mg of AastraZeneca LP, USA. Dosing periods of studies were separated by a washout period of 5 days.
Detailed description
An open Label, Randomized, 2-Period, 2-Treatment,2-Sequence, Crossover, Single-Dose Bioequivalence Study of Esomeprazole Mg DR Capsule containing Esomeprazole Mg 40 mg \[ Test Formulation, Torrent Pharmaceutical Ltd., India\] Versus Nexium 40 mg DR Capsule containing Esomeprazole 40 mg \[Reference Formulation, AastraZeneca LP, USA\] Under administered as the contents of capsule sprinkled over apple sauce in Healthy Human Volunteers Under Fasting Condition.
Interventions
DRUGNexium 40 mg DR Capsules of AstraZeneca LP, USA.
oral, crossover
oral, crossover
Sponsors
Torrent Pharmaceuticals Limited
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
* Sex: male * Age: 18-45 years * Volunteer with BMI of 18-27 (inclusive both) kg/m2 with minimum of 50 kg weight. * Healthy and willing to participate in the study. * Volunteer willing to adhere to the protocol requirements and to provide written informed consent. * Non-smokers or smoker who smokes less than 10 cigarettes per day.
Exclusion criteria
* Inability to communicate or co-operate. * Administration of any study drug in the period 0 to 3 months before entry to the study, * History of significant blood loss due to any reason, including blood donation in the past 3 months. * Volunteers suffering from any chronic illness such as arthritis, asthma etc. * History of pre-existing bleeding disorder. * Clinically relevant abnormalities in the results of the laboratory screening evaluation. * Clinically significant abnormal ECG or Chest X-ray. * HIV, HCV, HBsAg positive volunteers. * History of alcohol or drug abuse. * History of consumption of prescribed medication since last 14days or OTC medication/ herbal remedies since last 7 days before beginning of the study. * Positive to Breath alcohol test. * Opiate, tetra hydrocannabinol, amphetamine, barbiturates, benzodiazepines, Cocaine positive volunteers based on urine test. * Systolic blood pressure less than 100 mmHg or more than 140 mmHg and diastolic blood pressure less than 60 mm Hg or more than 90 mm Hg. * Pulse rate less than 50/minute or more than 100/minute. * Oral temperature less than 95°F or more than 98.6°F. * Respiratory rate less than 12/minute or more than 20/minute. * History of allergy to the test drug or any drug chemically similar to the drug under investigation. * Recent History of kidney or liver dysfunction. * Volunteers suffering from any psychiatric (acute or chronic) disorder. * Existence of any surgical or medical condition, which, in the judgment of the Chief Investigator and/or clinical investigator/physician, might interfere with the absorption; distribution,· metabolism or excretion of the drug or likely to compromise the safety of Volunteers.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | Pre-dose to 20 hour post dose | Pharmacokinetic Evaluation |
| AUC | Pre-dose to 20 hour post dose | Pharmacokinetic Evaluation |
Outcome results
None listed